Duna Raoof, MD
Ophthalmology · Laguna Hills, CANPI 1437389822
Payments from drug & device makers
Across 395 payments — averaging $284.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$41K
- Glaukos Corporation$27K
- Alcon Research LLC$17K
- Sight Sciences, Inc.$12K
- Rxsight Inc$8K
- Bausch & Lomb Americas Inc.$1K
- plus $6K from 22 others
What the payments were for
- Consulting fees$77,25269%
- Speaking & faculty fees$19,07617%
- Travel & lodging$4,3074%
- Food & beverage$11,81911%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 83 | $40,783 |
| Glaukos Corporation | 26 | $26,646 |
| Alcon Research LLC | 8 | $17,424 |
| Sight Sciences, Inc. | 44 | $12,368 |
| Rxsight Inc | 10 | $8,101 |
| Bausch & Lomb Americas Inc. | 31 | $1,265 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $945 |
| Dompe US, Inc. | 23 | $695 |
| Sun Pharmaceutical Industries Inc. | 30 | $663 |
| Ocular Therapeutix, Inc. | 29 | $626 |
| AbbVie(2 entities) | 20 | $571 |
| Biotissue Holdings Inc. | 8 | $494 |
| Novartis | 14 | $287 |
| Mallinckrodt Hospital Products Inc. | 9 | $247 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $186 |
| Oyster Point Pharma, Inc. | 6 | $175 |
| Shire North American Group Inc | 8 | $158 |
| Harrow Eye, LLC | 5 | $155 |
| Kala Pharmaceuticals, Inc. | 1 | $143 |
| Aerie Pharmaceuticals, Inc. | 6 | $101 |
| Amgen | 4 | $97 |
| NEW World Medical,inc. | 1 | $89 |
| Tarsus Pharmaceuticals, Inc. | 3 | $83 |
| Thea Pharma Inc. | 3 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Nova Eye, Inc. | 1 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epioxa$12,016
- OMNI(R) SURGICAL SYSTEM (US)$11,765
- ARGOS$9,986
- LIGHT ADJUSTABLE LENS (LAL)$7,700
- RXSIGHT CONTACT LENS$7,700
- RXSIGHT INJECTOR HANDPIECE$7,700
- RXSIGHT INJECTOR CARTRIDGE$7,700
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$7,700
- Clareon$7,143
- Travoprost Intraocular Implant - iDose$6,566
- LenSx$4,000
- Capella Aberrometer$3,675
- AcrySof IQ PanOptix$2,843
- AcrySof IQ VIVITY IOL$1,470
- CE-marked KXLA system$1,127
- Tecnis 1-piece IOL$762
- Tecnis 3-piece IOL$762
- Tecnis Symphony IOL$762
- Tecnis Symphony Toric IOL$762
- Centurion$735
How this compares
$112,468 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 35 | $43,515 |
| LumiganBimatoprost | 40 | $25,241 |
| MieboPerfluorohexyloctane/Pf | 28 | $23,311 |
| ProlensaBromfenac Sodium | 43 | $14,380 |
| Cyclosporine | 17 | $13,229 |
| RhopressaNetarsudil Mesylate | 18 | $8,698 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $6,679 |
| Prednisolone Acetate | 151 | $4,747 |
| Latanoprost | 289 | $3,081 |
| Bromfenac Sodium | 12 | $2,951 |
| Brimonidine Tartrate | 59 | $2,946 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $2,904 |
| Ofloxacin | 102 | $1,289 |
| Ketorolac Tromethamine | 91 | $1,221 |
| Timolol Maleate | 95 | $862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $571 | $71,66095 claims |
| Bausch & Lomb Americas Inc.Miebo | $1,265 | $23,31128 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $186 | $14,38043 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $101 | $8,69818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Laguna Hills
- John HovanesianLaguna Hills$3.7M
- Savak TeymoorianLaguna Hills$1.3M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.